In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the glob. India - 47% of revenues:12 brands among top 300 in India. Launched 37 new products including line extensions, out of which 13 were first in India launches. On the super specialty front, maintained leadership position in the Nephrology segment while in the Oncology space, the Company was the fastest growing Company in India.Rank 1st in the Nephrology segment in India. Zydus Wellness Limited (ZWL), a subsidiary, spearheads the group’s operations in the consumer wellness space. The Company continues to hold the leadership position in 5 out of 6 brands and has a base of over 30 crore consumers.In order to expand the presence globally,co. incorporated a wholly owned subsidiary in Bangladesh and entered into new geographies across SAARC, MEA and SEA regions. This division comprised sales of sugar-free which grew quickly from 152 Cr in FY08 to 452 Cr in FY13, beyond which growth slowed down and reached ~490 Cr in FY18. Zydus then acquired 4 products from Heinz (Glucon-D, Complan, Nycil, Sampriti Ghee) in 2018 at a cost of 4595 Cr, [10] which boostered sales to ~1738cr. in FY20. Co. operates in different countries of Asia Pacific, Africa, Middle East and Latin America.1st Position in Sri Lanka with a market share of 7.4% with 30 brands ranked as leaders in their respective molecule categories. 15 new launches in Brazil during FY22. The financials of the company looks good, RoNW is 13.7% and at CMP its looks fully priced. Price difference is around 17% and acceptance ratio as per current share holding for retail will be around 2% for retail, so final buyback ration may be near to 5-10% and one may get around 5-8% on investment. So we give AVOID rating to this buyback, those who are currently holding may participate in buyback.
✍️ Post a Comment